Umuthi Omusha Wophenyo Weziguli Ezibucayi Ze-Myeloid Leukemia

I-Priothera Ltd. namuhla imemezela ukuthi i-US Food and Drug Administration (FDA) inikeze imvume yokuqhubeka nesicelo seNkampani Sokuphenya Izidakamizwa Ezintsha (IND) ukuze iqale ucwaningo lwayo olubalulekile lweSigaba 2b/3 se-mocravimod (esiqanjwe ngokuthi i-MO-TRANS).

I-Priothera izoqala ucwaningo lwe-MO-TRANS lweSigaba 2b/3 somhlaba wonke eYurophu, e-US naseJapane, luhlola ukusebenza kahle nokuphepha kwe-mocravimod njenge-adjunctive and maintenance therapy ezigulini ezikhulile ze-Acute Myeloid Leukemia (AML) ezidlula i-allogen hematopoietic stem cell transplant (HSCT) ). Ucwaningo lwe-MO-TRANS kulindeleke ukuthi luqale engxenyeni yesibili ka-2022 futhi idatha yokuqala evela kulolu cwaningo kulindeleke ekupheleni kuka-2024.

I-Allogenic stem cell transplantation iyona ndlela kuphela engase yelaphe ezigulini ze-AML, nokho izinketho zokwelashwa zamanje zisahlotshaniswa nenani eliphezulu lemiphumela engemihle, kanye namazinga aphezulu okufa. 

U-Florent Gros, Umsunguli kanye Nomphathi Omkhulu we-Priothera, ubeke amazwana “Imvume ye-FDA IND yokuqala ucwaningo lwe-MO-TRANS lokuhlola i-mocravimod ezigulini ze-AML ezithola i-allogeneic HSCT kungenye ingqophamlando ye-Priothera. Sisendleleni yokuqala lolu cwaningo lomtholampilo olubalulekile lweSigaba 2b/3 futhi sibheke ngabomvu ukusebenza nethimba elikhulu labaphenyi abashisekayo kulo lonke elase-US, eYurophu nase-Asia, abahlanganyela umgomo wethu wokuletha i-mocravimod ezigulini njengendlela yokwelapha ehambisanayo neyokulungisa. ye-AML kanye nezinye izifo ezingase zibe khona ze-hematological."